Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Association of Prenatal Ultrasonography and Autism Spectrum Disorder.

Rosman NP, Vassar R, Doros G, DeRosa J, Froman A, DiMauro A, Santiago S, Abbott J.

JAMA Pediatr. 2018 Feb 12. doi: 10.1001/jamapediatrics.2017.5634. [Epub ahead of print]

PMID:
29435580
2.

Prediction of cognitive and motor development in preterm children using exhaustive feature selection and cross-validation of near-term white matter microstructure.

Schadl K, Vassar R, Cahill-Rowley K, Yeom KW, Stevenson DK, Rose J.

Neuroimage Clin. 2017 Nov 29;17:667-679. doi: 10.1016/j.nicl.2017.11.023. eCollection 2018.

3.

Seeds of Destruction: New Mechanistic Insights into the Role of Apolipoprotein E4 in Alzheimer's Disease.

Vassar R.

Neuron. 2017 Dec 6;96(5):953-955. doi: 10.1016/j.neuron.2017.11.022.

PMID:
29216455
4.

A Becn1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease.

Rocchi A, Yamamoto S, Ting T, Fan Y, Sadleir K, Wang Y, Zhang W, Huang S, Levine B, Vassar R, He C.

PLoS Genet. 2017 Aug 14;13(8):e1006962. doi: 10.1371/journal.pgen.1006962. eCollection 2017 Aug.

5.

APP mouse models for Alzheimer's disease preclinical studies.

Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, Saido TC.

EMBO J. 2017 Sep 1;36(17):2473-2487. doi: 10.15252/embj.201797397. Epub 2017 Aug 1. Review.

6.

Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid-β Protein Precursor Transgenic Mice.

Liu P, Reichl JH, Rao ER, McNellis BM, Huang ES, Hemmy LS, Forster CL, Kuskowski MA, Borchelt DR, Vassar R, Ashe KH, Zahs KR.

J Alzheimers Dis. 2017;56(2):743-761. doi: 10.3233/JAD-161027.

7.

HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation.

Gannon PJ, Akay-Espinoza C, Yee AC, Briand LA, Erickson MA, Gelman BB, Gao Y, Haughey NJ, Zink MC, Clements JE, Kim NS, Van De Walle G, Jensen BK, Vassar R, Pierce RC, Gill AJ, Kolson DL, Diehl JA, Mankowski JL, Jordan-Sciutto KL.

Am J Pathol. 2017 Jan;187(1):91-109. doi: 10.1016/j.ajpath.2016.09.006.

8.

Identification of natural products with neuronal and metabolic benefits through autophagy induction.

Fan Y, Wang N, Rocchi A, Zhang W, Vassar R, Zhou Y, He C.

Autophagy. 2017 Jan 2;13(1):41-56. doi: 10.1080/15548627.2016.1240855. Epub 2016 Oct 28.

9.

Astrocytes from old Alzheimer's disease mice are impaired in Aβ uptake and in neuroprotection.

Iram T, Trudler D, Kain D, Kanner S, Galron R, Vassar R, Barzilai A, Blinder P, Fishelson Z, Frenkel D.

Neurobiol Dis. 2016 Dec;96:84-94. doi: 10.1016/j.nbd.2016.08.001. Epub 2016 Aug 17.

PMID:
27544484
10.

Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.

Yan R, Fan Q, Zhou J, Vassar R.

Neurosci Biobehav Rev. 2016 Jun;65:326-40. doi: 10.1016/j.neubiorev.2016.03.025. Epub 2016 Apr 1. Review.

11.

Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease.

Sadleir KR, Kandalepas PC, Buggia-Prévot V, Nicholson DA, Thinakaran G, Vassar R.

Acta Neuropathol. 2016 Aug;132(2):235-56. doi: 10.1007/s00401-016-1558-9. Epub 2016 Mar 18.

12.

Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.

Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM.

Acta Neuropathol Commun. 2015 Nov 10;3:70. doi: 10.1186/s40478-015-0250-y.

13.

Neonatal brain microstructure correlates of neurodevelopment and gait in preterm children 18-22 mo of age: an MRI and DTI study.

Rose J, Cahill-Rowley K, Vassar R, Yeom KW, Stecher X, Stevenson DK, Hintz SR, Barnea-Goraly N.

Pediatr Res. 2015 Dec;78(6):700-8. doi: 10.1038/pr.2015.157. Epub 2015 Aug 31.

PMID:
26322412
14.

Neonatal Biomarkers of Inflammation: Correlates of Early Neurodevelopment and Gait in Very-Low-Birth-Weight Preterm Children.

Rose J, Vassar R, Cahill-Rowley K, Hintz SR, Stevenson DK.

Am J Perinatol. 2016 Jan;33(1):71-8. doi: 10.1055/s-0035-1557106. Epub 2015 Jul 24.

PMID:
26212060
15.

Epac2 Mediates cAMP-Dependent Potentiation of Neurotransmission in the Hippocampus.

Fernandes HB, Riordan S, Nomura T, Remmers CL, Kraniotis S, Marshall JJ, Kukreja L, Vassar R, Contractor A.

J Neurosci. 2015 Apr 22;35(16):6544-53. doi: 10.1523/JNEUROSCI.0314-14.2015.

16.

BACE1 inhibitor drugs in clinical trials for Alzheimer's disease.

Vassar R.

Alzheimers Res Ther. 2014 Dec 24;6(9):89. doi: 10.1186/s13195-014-0089-7. eCollection 2014.

17.

Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.

Sadleir KR, Eimer WA, Cole SL, Vassar R.

Mol Neurodegener. 2015 Jan 7;10:1. doi: 10.1186/1750-1326-10-1.

18.

Movement disorders due to bilirubin toxicity.

Rose J, Vassar R.

Semin Fetal Neonatal Med. 2015 Feb;20(1):20-25. doi: 10.1016/j.siny.2014.11.002. Epub 2014 Dec 16. Review.

19.

Identification of neonatal white matter on DTI: influence of more inclusive thresholds for atlas segmentation.

Vassar RL, Barnea-Goraly N, Rose J.

PLoS One. 2014 Dec 15;9(12):e115426. doi: 10.1371/journal.pone.0115426. eCollection 2014.

20.

Motor systems and postural instability.

Vassar RL, Rose J.

Handb Clin Neurol. 2014;125:237-51. doi: 10.1016/B978-0-444-62619-6.00015-X. Review.

PMID:
25307579
21.

Molecular neurodegeneration: basic biology and disease pathways.

Vassar R, Zheng H.

Mol Neurodegener. 2014 Sep 23;9:34. doi: 10.1186/1750-1326-9-34.

22.

Neonatal physiological correlates of near-term brain development on MRI and DTI in very-low-birth-weight preterm infants.

Rose J, Vassar R, Cahill-Rowley K, Stecher Guzman X, Hintz SR, Stevenson DK, Barnea-Goraly N.

Neuroimage Clin. 2014 Jun 2;5:169-77. doi: 10.1016/j.nicl.2014.05.013. eCollection 2014.

23.

Low-level laser therapy ameliorates disease progression in a mouse model of Alzheimer's disease.

Farfara D, Tuby H, Trudler D, Doron-Mandel E, Maltz L, Vassar RJ, Frenkel D, Oron U.

J Mol Neurosci. 2015 Feb;55(2):430-6. doi: 10.1007/s12031-014-0354-z. Epub 2014 Jul 4.

PMID:
24994540
24.

Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.

Sadleir KR, Eimer WA, Kaufman RJ, Osten P, Vassar R.

PLoS One. 2014 Jul 3;9(7):e101643. doi: 10.1371/journal.pone.0101643. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e110914.

25.

The normal and pathologic roles of the Alzheimer's β-secretase, BACE1.

Kandalepas PC, Vassar R.

Curr Alzheimer Res. 2014;11(5):441-9. Review.

26.

Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer's disease.

Kukreja L, Kujoth GC, Prolla TA, Van Leuven F, Vassar R.

Mol Neurodegener. 2014 May 2;9:16. doi: 10.1186/1750-1326-9-16.

27.

Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects.

Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF.

J Neurochem. 2014 Jul;130(1):4-28. doi: 10.1111/jnc.12715. Epub 2014 Apr 19. Review.

28.

Targeting the β secretase BACE1 for Alzheimer's disease therapy.

Yan R, Vassar R.

Lancet Neurol. 2014 Mar;13(3):319-29. doi: 10.1016/S1474-4422(13)70276-X. Epub 2014 Feb 17. Review.

29.

Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase.

Buggia-Prévot V, Fernandez CG, Riordan S, Vetrivel KS, Roseman J, Waters J, Bindokas VP, Vassar R, Thinakaran G.

Mol Neurodegener. 2014 Jan 4;9:1. doi: 10.1186/1750-1326-9-1.

30.

A function for EHD family proteins in unidirectional retrograde dendritic transport of BACE1 and Alzheimer's disease Aβ production.

Buggia-Prévot V, Fernandez CG, Udayar V, Vetrivel KS, Elie A, Roseman J, Sasse VA, Lefkow M, Meckler X, Bhattacharyya S, George M, Kar S, Bindokas VP, Parent AT, Rajendran L, Band H, Vassar R, Thinakaran G.

Cell Rep. 2013 Dec 26;5(6):1552-63. doi: 10.1016/j.celrep.2013.12.006.

31.

ADAM10 prodomain mutations cause late-onset Alzheimer's disease: not just the latest FAD.

Vassar R.

Neuron. 2013 Oct 16;80(2):250-3. doi: 10.1016/j.neuron.2013.09.031.

32.

Brain microstructural development at near-term age in very-low-birth-weight preterm infants: an atlas-based diffusion imaging study.

Rose J, Vassar R, Cahill-Rowley K, Guzman XS, Stevenson DK, Barnea-Goraly N.

Neuroimage. 2014 Feb 1;86:244-56. doi: 10.1016/j.neuroimage.2013.09.053. Epub 2013 Oct 1.

33.

Elevated Aβ42 in aged, non-demented individuals with cerebral atherosclerosis.

Sadleir KR, Bennett DA, Schneider JA, Vassar R.

Curr Alzheimer Res. 2013 Oct;10(8):785-9.

34.

The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques.

Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R.

Acta Neuropathol. 2013 Sep;126(3):329-52. doi: 10.1007/s00401-013-1152-3. Epub 2013 Jul 3. Erratum in: Acta Neuropathol. 2013 Oct;126(4):623.

35.

Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models.

Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, Ervin FR, Snigdha S, Cotman CW, Saido TC, Vassar RJ, St George-Hyslop P, Ikezu T, Schilling S, Demuth HU, Lemere CA.

Am J Pathol. 2013 Aug;183(2):369-81. doi: 10.1016/j.ajpath.2013.05.005. Epub 2013 Jun 7.

36.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS.

Science. 2013 May 24;340(6135):924-f. doi: 10.1126/science.1235505.

37.
38.

Molecular Differences and Similarities Between Alzheimer's Disease and the 5XFAD Transgenic Mouse Model of Amyloidosis.

Maarouf CL, Kokjohn TA, Whiteside CM, Macias MP, Kalback WM, Sabbagh MN, Beach TG, Vassar R, Roher AE.

Biochem Insights. 2013 Nov 21;6:1-10. doi: 10.4137/BCI.S13025. eCollection 2013.

39.

Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies.

Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H.

J Biol Chem. 2013 Jan 11;288(2):1295-306. doi: 10.1074/jbc.M112.409250. Epub 2012 Nov 15.

40.

Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice.

Perez SE, Nadeem M, Sadleir KR, Matras J, Kelley CM, Counts SE, Vassar R, Mufson EJ.

Int J Physiol Pathophysiol Pharmacol. 2012;4(3):115-27. Epub 2012 Sep 20.

41.

β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects.

Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, Vassar R.

J Biol Chem. 2012 Nov 9;287(46):38408-25. doi: 10.1074/jbc.M112.415505. Epub 2012 Sep 17.

42.
43.
44.

Identification and biology of β-secretase.

Kandalepas PC, Vassar R.

J Neurochem. 2012 Jan;120 Suppl 1:55-61. doi: 10.1111/j.1471-4159.2011.07512.x. Epub 2011 Nov 28. Review.

45.

The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis.

Zhao J, O'Connor T, Vassar R.

J Neuroinflammation. 2011 Nov 2;8:150. doi: 10.1186/1742-2094-8-150.

46.

The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease.

Vassar R, Kandalepas PC.

Alzheimers Res Ther. 2011 May 31;3(3):20. doi: 10.1186/alzrt82.

47.

Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models.

Frydman-Marom A, Levin A, Farfara D, Benromano T, Scherzer-Attali R, Peled S, Vassar R, Segal D, Gazit E, Frenkel D, Ovadia M.

PLoS One. 2011 Jan 28;6(1):e16564. doi: 10.1371/journal.pone.0016564.

48.

Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations.

Youmans KL, Leung S, Zhang J, Maus E, Baysac K, Bu G, Vassar R, Yu C, LaDu MJ.

J Neurosci Methods. 2011 Mar 15;196(1):51-9. doi: 10.1016/j.jneumeth.2010.12.025. Epub 2011 Jan 8.

49.

BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization.

Hitt BD, Jaramillo TC, Chetkovich DM, Vassar R.

Mol Neurodegener. 2010 Aug 23;5:31. doi: 10.1186/1750-1326-5-31.

50.

The secretases: enzymes with therapeutic potential in Alzheimer disease.

De Strooper B, Vassar R, Golde T.

Nat Rev Neurol. 2010 Feb;6(2):99-107. doi: 10.1038/nrneurol.2009.218. Review.

Supplemental Content

Loading ...
Support Center